Pulmonary Fibrosis

HomePatientsLung Disease Week at the ATS2015Pulmonary Fibrosis ▶ Information for Experts
Information for Experts

Pulmonary Fibrosis Week

ClinicianATS Educational Products on Pulmonary Fibrosis

 

2014

A95 SKYFALL: LATE BREAKING CLINICAL TRIALS IN IDIOPATHIC PULMONARY FIBROSIS
B2 THE EVOLVING ROLE OF GENETICS IN THE CARE OF PULMONARY FIBROSIS
D2 BEYOND IPF: MANAGEMENT DILEMMAS IN CHRONIC FIBROTIC ILD
D82 CHALLENGES AND CONSIDERATIONS IN THE MANAGEMENT OF PATIENTS WITH CYSTIC FIBROSIS: BEYOND ROUTINE CARE AND EXACERBATIONS
WS7 MANAGEMENT OF OLDER ADULTS WITH CYSTIC FIBROSIS

2013

A91 THERAPEUTIC STRATEGIES IN IDIOPATHIC PULMONARY FIBROSIS: DEBATES BETWEEN BENCH AND BEDSIDE: A PRO-CON DEBATE
D2 ADDING INSULT TO INJURY: COMPLICATIONS OF IDIOPATHIC PULMONARY FIBROSIS
D86 IMMUNE DYSREGULATION IN PULMONARY FIBROSIS

For Best of ATS Conferences materials visit the following link : https://store.thoracic.org/

 


 

ClinicianATS Journals on Pulmonary Fibrosis

 

AJRCCM

  • Pirfenidone for Idiopathic Pulmonary Fibrosis, Thrombocytosis in Chronic Obstructive Pulmonary Disease Exacerbations, and a Longitudinal Study on E-Cigarettes
    Vol. 190, No. 6 (2014), pp. 699-700
    Read Abstract
  • Wnt/β-Catenin and Transforming Growth Factor-β Signaling in Pulmonary Fibrosis. A Case for Antagonistic Pleiotropy?
    Vol. 190, No. 2 (2014), pp. 129-131
    Read Abstract
  • miR-31 Dysregulation in Cystic Fibrosis Airways Contributes to Increased Pulmonary Cathepsin S Production
    Vol. 190, No. 2 (2014), pp. 165-174
    Read Abstract
  • Distinct Differences in Gene Expression Patterns in Pulmonary Arteries of Patients with Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis with Pulmonary Hypertension
    Vol. 190, No. 1 (2014), pp. 98-111
    Read Abstract
  • A Clinical Prediction Tool for Prognosis in Patients with Cystic Fibrosis, Short-Term Glucocorticoid Therapy for Chronic Obstructive Pulmonary Disease, and Laryngeal Ultrasound for Prediction of Postextubation Laryngeal Edema
    Vol. 189, No. 4 (2014), pp. 482-483.
    Read Abstract
  • The Lung Microbiome in Idiopathic Pulmonary Fibrosis. What Does It Mean and What Should We Do about It?
    Vol. 190, No. 8 (2014), pp. 850-852.
    Read Abstract
  • All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials
    Vol. 189, No. 7 (2014), pp. 825-831.
    Read Abstract
  • Wnt/β-Catenin and Transforming Growth Factor-β Signaling in Pulmonary Fibrosis. A Case for Antagonistic Pleiotropy?
    Vol. 190, No. 2 (2014), pp. 129-131.
    Read Abstract

AJRCMB

  • Danger-Associated Molecular Patterns and Danger Signals in Idiopathic Pulmonary Fibrosis
    Vol. 51, No. 2 (2014), pp. 163-168
    Read Abstract
  • MicroRNA-326 Regulates Profibrotic Functions of Transforming Growth Factor-β in Pulmonary Fibrosis
    Vol. 50, No. 5 (2014), pp. 882-892
    Read Abstract 
  • Targeting Interleukin-13 with Tralokinumab Attenuates Lung Fibrosis and Epithelial Damage in a Humanized SCID Idiopathic Pulmonary Fibrosis Model
    Vol. 50, No. 5 (2014), pp. 985-994
    Read Abstract
  • Inhibition of Transglutaminase 2, a Novel Target for Pulmonary Fibrosis, by Two Small Electrophilic Molecules
    Vol. 50, No. 4 (2014), pp. 737-747
    Read Abstract 
  • Bone Marrow–Derived Stromal Cells Are Invasive and Hyperproliferative and Alter Transforming Growth Factor-α–Induced Pulmonary Fibrosis
    Vol. 50, No. 4 (2014), pp. 777-786
    Read Abstract
  • Tumor Necrosis Factor-α Accelerates the Resolution of Established Pulmonary Fibrosis in Mice by Targeting Profibrotic Lung Macrophages
    Vol. 50, No. 4(2014), pp. 825-837
    Read Abstract
  • Fibroblast Growth Factor 2 Is Required for Epithelial Recovery, but Not for Pulmonary Fibrosis, in Response to Bleomycin
    Vol.52, No. 1 (2015), pp. 116-128.
    Read Abstract
  • An Inhibitor of NADPH Oxidase-4 Attenuates Established Pulmonary Fibrosis in a Rodent Disease Model
    Vol. 50, No. 1 (2014), pp. 158-169.
    Read Abstract

Annals of ATS

  • Lung Microbiome Predicts Disease Progression in Idiopathic Pulmonary Fibrosis
    Vol. 11, No. Supplement 1 (2014), pp. S79-S80
    Read Abstract
  • Increasing Global Mortality from Idiopathic Pulmonary Fibrosis in the Twenty-First Century
    Vol. 11, No. 8 (2014), pp. 1176-1185.
    Read Abstract
  • Embracing Complex Diseases. The Case for an Idiopathic Pulmonary Fibrosis Biorepository
    Vol. 11, No. 8 (2014), pp. 1248-1249.
    Read Abstract

 


 

Clinician ATS Statements, Guidelines and Reports

ATS Statements, Guidelines and Reports are printed in the American Journal of Respiratory and Critical Care Medicine. These documents are also available in PDF format. You may download one copy of any ATS document; there is no charge for this service.